Session Title: Combination with Confidence: Finerenone for Kidney and Heart Protection
Organized by: Bayer AG
Session Description:
This symposium will examine how multi-pathway, biomarker-guided CKD therapies enable earlier, more personalized care, including the nuanced interpretation of short-term eGFR changes. Faculty will discuss albuminuria as a modifiable driver of cardiovascular risk and CKD progression and will explore the potential of finerenone and SGLT2 inhibitor combination therapy in patients with microalbuminuria and eGFR <60. The role of finerenone as an emerging pillar of CKM care, with dual CKD and HF benefits, will also be highlighted. Real-world cases and a multidisciplinary panel discussion will help translate current evidence into practical clinical decision-making.
Learning Objectives:
1. Understand the importance of aligning therapy choice with patient goals, including how findings from the CONFIDENCE trial can help to guide treatment decisions
2. Learn about clinical considerations when managing CKD with finerenone and SGLT2i combination therapy
3. Explore current and future opportunities to manage CKD and HF with finerenone, with particular importance on early intervention
| Time | Session |
|---|---|
|
12:50 p.m.
12:55 p.m.
|
|
|
12:55 p.m.
1:05 p.m.
|
|
|
1:05 p.m.
1:20 p.m.
|
|
|
1:20 p.m.
1:30 p.m.
|
|
|
1:30 p.m.
1:40 p.m.
|
|
|
1:40 p.m.
1:50 p.m.
|
|